Your Month-by-Month Wegovy Investment Breakdown
Wegovy Dosage Chart: Complete UK Monthly Cost Analysis
The Wegovy dosage chart follows a mandatory 16-week escalation protocol, with each phase carrying distinct monthly costs in the UK market. Understanding this financial commitment upfront helps patients budget effectively for long-term weight management success. Month 1-4 begins at £79.99 for the 0.25mg starter dose, progressing to £94.99 for months 5-8 (0.5mg), then £99.99 for months 9-12 (1mg), and £139.99 for months 13-16 (1.7mg). The maintenance phase from month 17 onwards costs £209.99 monthly for the 2.4mg dose, representing your ongoing investment in sustained weight management.
This structured Wegovy dosage chart ensures your body gradually adapts to semaglutide, minimising gastrointestinal side effects whilst maximising therapeutic benefit. The total cost for your initial 16-week escalation period amounts to £623.96 across four different dose strengths. Once you reach the 2.4mg maintenance dose, you can expect consistent monthly costs of £209.99, making annual budgeting straightforward at approximately £2,519.88 for ongoing treatment. Our GPhC-registered pharmacy (#9012878) maintains these competitive prices through our DOSE25 discount programme for returning customers.
Wegovy Dosage Chart Pricing: Bundles vs Individual Purchases
Our Wegovy dosage chart pricing includes strategic bundle options designed for treatment convenience rather than pure cost savings. The Intro Duo bundle (0.25mg & 0.5mg) costs £169.99, covering your first 8 weeks of treatment in a single order with assured cold-chain delivery. For patients wanting extended supply security, the Progress Trio (0.5mg, 1mg & 1.7mg) provides three consecutive dose strengths for £369.99, eliminating multiple ordering requirements during your escalation phase.
The Ultimate Stability Trio represents our most popular maintenance option, providing three months of 2.4mg supply for £649.99 once you've completed the Wegovy dosage chart escalation. This bundle approach reduces ordering frequency whilst ensuring uninterrupted treatment continuation. New customers apply code FIRST40 at checkout, whilst returning customers use DOSE25 to access these prices. Our clinical team (GPhC #9012878) recommends bundle purchasing for patients committed to the full treatment protocol, as supply continuity is crucial for maintaining therapeutic semaglutide levels.
Clinical Evidence Supporting Wegovy Dosage Chart Protocol
The Wegovy dosage chart escalation protocol is based on robust clinical evidence from the STEP trial programme. In STEP 1, patients following this exact dosing schedule alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks, compared to 2.4% with placebo (Wilding et al., NEJM, 2021). The mandatory dose escalation helps patients reach therapeutic semaglutide levels whilst minimising treatment discontinuation due to gastrointestinal side effects.
STEP 5 trial data demonstrates that patients maintaining the 2.4mg dose achieved sustained clinically studied weight loss at two years, validating the long-term cost investment in maintenance therapy. However, the same study showed patients regained approximately two-thirds of weight lost within one year of stopping treatment, emphasising that the Wegovy dosage chart represents a long-term financial and lifestyle commitment. These clinical outcomes help justify the monthly investment required for sustained weight management success.
How Wegovy Works Throughout the Dosage Chart
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural fullness hormone to reduce appetite and promote satiety after smaller meals. As you progress through the Wegovy dosage chart from 0.25mg to 2.4mg, semaglutide levels gradually increase, enhancing appetite suppression and potentially reducing food cravings by acting on brain appetite centres. The slow dose escalation allows your digestive system to adapt whilst building therapeutic semaglutide concentrations. Each weekly injection using the FlexTouch pen provides consistent drug release, maintaining steady appetite control between doses. This mechanism explains why skipping doses or stopping treatment often leads to appetite returning to pre-treatment levels, making the financial commitment to maintenance therapy crucial for sustained results.
Wegovy Dosage Chart: Streamlined UK Ordering Process
Accessing your Wegovy dosage chart treatment through EverydayMeds begins with our 3-minute online clinical assessment, covering your BMI, weight-related health conditions, and previous weight management attempts. Our UK prescribers review applications within 3 working days (or 24 hours with express service), ensuring you meet MHRA licensing criteria for this prescription-only medicine. Once approved, your chosen dose ships via next-day delivery using temperature-controlled cold-chain packaging to maintain semaglutide stability. Our system tracks your progress through the dosage chart, sending timely reminders for your next dose strength to prevent treatment interruptions. This seamless process ensures you can focus on your weight management goals whilst we handle the clinical and logistics complexities.
Wegovy Dosage Chart: Storage and Practical Considerations
Proper storage throughout your Wegovy dosage chart journey is essential for maintaining semaglutide potency and your investment value. Unopened pens must be refrigerated at 2-8°C, but offer 6 weeks of room temperature stability below 30°C once removed from the fridge - superior to Mounjaro's 21-day limit for travel convenience. Each FlexTouch pen contains 4 doses for weekly injection, meaning your monthly supply requires careful temperature management. The pre-filled pen design eliminates measuring errors during dose escalation phases, ensuring you receive precise semaglutide amounts at each stage. Understanding these storage requirements helps protect your monthly investment whilst ensuring optimal therapeutic outcomes throughout the 16-week escalation protocol.
Long-term Wegovy Dosage Chart Cost Planning for UK Patients
Successful weight management requires viewing the Wegovy dosage chart as a long-term financial commitment rather than a short-term intervention. Based on STEP trial data showing weight regain after treatment cessation, most patients require ongoing maintenance therapy to preserve weight loss benefits. At £209.99 monthly for the 2.4mg maintenance dose, annual costs total approximately £2,519.88 - comparable to many patients' annual gym memberships, meal replacement programmes, or private healthcare costs.
Our DOSE25 programme ensures returning customers maintain competitive pricing throughout their maintenance phase, providing cost predictability for annual budgeting. Many patients find the maintenance investment worthwhile when considering potential savings on larger clothing sizes, reduced healthcare costs from weight-related conditions, and improved quality of life measures. The key is viewing your Wegovy dosage chart investment as preventive healthcare spending rather than short-term weight loss costs.
Wegovy Dosage Chart Investment: Getting Started Today
Beginning your Wegovy dosage chart journey starts with understanding the total financial commitment and having realistic expectations about ongoing costs. Your first month costs £79.99 with code FIRST40, providing an affordable entry point to assess treatment tolerance and early response. Our clinical assessment takes just 3 minutes, with most patients approved within 72 hours for this prescription-only medicine. We recommend reviewing your annual healthcare budget to ensure you can commit to the full escalation protocol plus at least 6 months of maintenance therapy for meaningful results. Our GPhC-registered pharmacy (#9012878) provides ongoing clinical support throughout your treatment journey, helping optimise both therapeutic outcomes and cost-effectiveness. Visit https://everydaymeds.co.uk/collections/wegovy to begin your clinical assessment and secure your starting dose today.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
